3 things to expect from Novavax in 2021

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Novavax Inc (NASDAQ: NVAX) shares gained more than 2,600% last year as the clinical-stage biotech became one of the front-runners in the race to develop a coronavirus vaccine — and was awarded $1.6 billion from the United States Government to support its efforts.

That was a genuinely amazing performance, and as 2021 begins, Novavax still has a lot on its agenda. Here are three things investors should be looking for from the company this year.

1. A possible coronavirus vaccine — and revenue

Novavax has a late-stage clinical trial for its coronavirus vaccine candidate, NVX-CoV2373, well underway in the United Kingdom, and…